Business Wire

Retrospective Analysis of Data Evaluating Safety and Efficacy of REBYOTA™ (fecal microbiota, live – jslm) in a Real-World Patient Population with Comorbidities and Risk ...

REBYOTA is indicated for the prevention of recurrence of Clostridioides difficile (C. diff) infection in individuals 18 years of age and older, following antibiotic treatment for recurrent C. diff ...
Healio

Gut microbiome restored, 6-month safety confirmed with Rebyota via colonoscopy

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Most patients (92.7%) with recurrent C. difficile ...
Healio

‘This works’: Rebyota safe, effective when given by colonoscopy for recurrent C. difficile

Please provide your email address to receive an email when new articles are posted on . Ninety-five percent of patients achieved treatment success at 8 weeks after administration of Rebyota via ...
Yahoo Finance

REBYOTA (RBX2660) Drug Insight and Market Forecasts, 2032: Focus on United States, Germany, France, Italy, Spain United Kingdom, and Japan

Dublin, Dec. 14, 2023 (GLOBE NEWSWIRE) -- The "REBYOTA Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. This report provides comprehensive insights ...